Skip to content
Peptigraph home
Shop Peptides50% off*

Does retatrutide cause diarrhea?

Yes. In the TRIUMPH-2 phase 3 trial, 27%, 34% and 34% of participants on the three retatrutide doses had diarrhoea, against 13% on placebo.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Yes. In the TRIUMPH-2 phase 3 trial, 27%, 34% and 34% of participants on the three retatrutide doses had diarrhoea, against 13% on placebo.[1]

The same abstract calls gastrointestinal events the most frequent adverse events and says they were more common on retatrutide than on placebo.[1]

Course and dose pattern

In the phase 3 monotherapy trial in type 2 diabetes, the common gastrointestinal events were generally mild to moderate and subsided over time.[2]

A review of the highest phase 2 doses attributes the extra gastrointestinal events, diarrhoea among them, to rapid dose escalation and a higher starting dose.[3]

In the phase 2 type 2 diabetes registry results, diarrhoea affected 2 of 45 placebo participants and 7 of 46 in the top-dose step-up arm.[4]

EG007 is the diabetes phase 2 arm that began at 2 mg and ended at 12 mg.[4]

Common questions

Can retatrutide cause diarrhea in people with type 2 diabetes?

Yes. A phase 3 trial in adults with obesity and type 2 diabetes recorded diarrhoea more often on retatrutide than on placebo.[1]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  2. 2Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  3. 3Retatrutide in type 2 diabetes mellitus and obesity: an overview.Expert review of clinical pharmacology · 2026PMID 41785010Accessed 2 Oct 2026
  4. 4A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.